OncoCyte Reports Third Quarter 2018 Financial Results and Progress in DetermaVu™ Development
November 13, 2018 16:05 ET
|
OncoCyte Corporation
Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2019 Development Plan Remains On-Track, Targeting Commercial...
Oncocyte to Report Third Quarter 2018 Financial Results on November 13, 2018
November 06, 2018 09:00 ET
|
OncoCyte Corporation
ALAMEDA, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will...
OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies
October 29, 2018 16:05 ET
|
OncoCyte Corporation
Initiates Algorithm Development Study to Establish Accuracy in Interpreting Assay Results On-Track for Pivotal R&D Validation Study Results by Approximately Year End, with Commercial Availability...
OncoCyte Corporation to Present at the BIO CEO Investor Forum
October 17, 2018 08:00 ET
|
OncoCyte Corporation
ALAMEDA, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William...
OncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments
August 14, 2018 16:10 ET
|
OncoCyte Corporation
-Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2018 ...
Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte
August 09, 2018 16:10 ET
|
OncoCyte Corporation
ALAMEDA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today...
OncoCyte to Report Second Quarter 2018 Financial Results on August 14, 2018
July 30, 2018 07:00 ET
|
OncoCyte Corporation
ALAMEDA, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced...
OncoCyte Announces At-Market $3.59 Million Offering of Common Stock and Warrants
July 27, 2018 09:00 ET
|
OncoCyte Corporation
ALAMEDA, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer,...
OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test
July 09, 2018 16:10 ET
|
OncoCyte Corporation
- Results suggest improved performance of next-generation test- Study results support move to new diagnostic testing platform- Significant development work required to fully validate this recent...
OncoCyte Reports First Quarter 2018 Financial Results
May 15, 2018 16:10 ET
|
OncoCyte Corporation
ALAMEDA, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and...